Next Article in Journal
Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease
Previous Article in Journal
T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation
Open AccessReview

The Role of Angiogenesis in Cancer Treatment

Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2017, 5(2), 34; https://doi.org/10.3390/biomedicines5020034
Received: 2 May 2017 / Revised: 9 June 2017 / Accepted: 15 June 2017 / Published: 21 June 2017
(This article belongs to the Special Issue Anti-Angiogenesis Therapeutics in Cancer)
A number of anti-angiogenesis drugs have been FDA-approved and are being used in cancer treatment, and a number of other agents are in different stages of clinical development or in preclinical evaluation. However, pharmacologic anti-angiogenesis strategies that arrest tumor progression might not be enough to eradicate tumors. Decreased anti-angiogenesis activity in single mechanism-based anti-angiogenic strategies is due to the redundancy, multiplicity, and development of compensatory mechanism by which blood vessels are remodeled. Improving anti-angiogenesis drug efficacy will require identification of broad-spectrum anti-angiogenesis targets. These strategies may have novel features, such as increased porosity, and are the result of complex interactions among endothelial cells, extracellular matrix proteins, growth factors, pericyte, and smooth muscle cells. Thus, combinations of anti-angiogenic drugs and other anticancer strategies such as chemotherapy appear essential for optimal outcome in cancer patients. This review will focus on the role of anti-angiogenesis strategies in cancer treatment. View Full-Text
Keywords: physiological angiogenesis; pathological angiogenesis; pro-angiogenesis; anti-angiogenesis; endothelial cells; pericyte; integrin; matrix metalloproteinase; vascular growth factors; anti-VEGF; anti-integrin; tyrosine kinase inhibitors physiological angiogenesis; pathological angiogenesis; pro-angiogenesis; anti-angiogenesis; endothelial cells; pericyte; integrin; matrix metalloproteinase; vascular growth factors; anti-VEGF; anti-integrin; tyrosine kinase inhibitors
Show Figures

Graphical abstract

MDPI and ACS Style

Rajabi, M.; Mousa, S.A. The Role of Angiogenesis in Cancer Treatment. Biomedicines 2017, 5, 34. https://doi.org/10.3390/biomedicines5020034

AMA Style

Rajabi M, Mousa SA. The Role of Angiogenesis in Cancer Treatment. Biomedicines. 2017; 5(2):34. https://doi.org/10.3390/biomedicines5020034

Chicago/Turabian Style

Rajabi, Mehdi; Mousa, Shaker A. 2017. "The Role of Angiogenesis in Cancer Treatment" Biomedicines 5, no. 2: 34. https://doi.org/10.3390/biomedicines5020034

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop